AnaMar strives to develop biomarkers that clearly describe the pathogenesis in chronic joint diseases, and are able to diagnose arthritis as well as establish a prognosis of the outcome for patients with chronic joint diseases.

The biomarker development at AnaMar has the dual objective of supporting our drug development work and of developing into an independent profitable business area. A key is therefore that the biomarkers can be used to assess endpoints in one or more of our drug development projects. At the same time, AnaMar is developing biomarkers for use in the broader research and development field and possibly also for clinical use. AnaMar believes this provides a significant competitive advantage in that the biomarker development strongly supports the company's core drug development projects.

We believe that our biomarker research and development (i) increases the understanding of drug action, efficacy and/or safety, (ii) enables better and earlier diagnosis of the various forms of arthritis, (iii) facilitates therapy response prediction, (iv) expands the molecular definition of the disease, and (v) helps select patients for clinical trial evaluation.

The company currently has two biomarker assays on the market. One of these is intended for human use and the other for animal use in connection with research and development.

We are evaluating and developing several new biomarkers, including new variants of COMP (neo-epitopes) and a novel biomarker possibly specific for OA. In addition, there are several other new project ideas at various stages in the pipeline being explored.